Passive immunotherapeutics are important in post exposure prophylaxis and treatment of infectious diseases. Reagents for passive immunotherapy include convalescent sera and monoclonal antibodies (mAb). Murine, humanized and fully human mAb (fhmAb) share advantages with respect to defined specificity, and enhanced safety profiles. However, only fhmAb possess native effector functions and eliminate risk of immune responses to nonhuman components that have the potential to reduce efficacy and/or cause autoimmune disease. FhmAb that neutralize Rift Valley fever virus (RVFV), Nipah/Hendra virus (NiV/HeV), and West Nile virus (WNV) were created using a fully human fusion partner cell line (MFP-2) and PEL from patients after natural infection (NiV and WNV) or vaccination (RVFV).
In Aim 1 of this project we will characterize these fhmAb in vivo. PBL from immune donors can difficult to obtain, particularly early in the course of an outbreak;thus, alternative strategies are needed whereby fhmAbs with optimized reactivity can be generated using synthetic reagents and in vitro maturation methods. Toward this end we will test (in Aims 2 and 3) the utility of a genetically engineered Veloclmmune? mouse for producing fhmAb from recombinant antigens representing NiV and Chikungunya virus (CHIKV). Functionality of Veloclmmune-drived mAb to NiV will be compared to that of the mAb generated with MFP-2. Furthermore, (Aim 4) we will apply two complementary methods for in vitro optimization of mAb reactivity: a yeast dual-display system that allows for in vitro mutation of cloned sequences followed by high throughput selection of reactive variants in a yeast system, and somatic hypermutation using the Ramos cell and/or activation induced cytidine deaminase (AID) systems.
Specific Aims are: (1) Characterize biological efficacy of existing fhmAb to RVFV, NiV/HeV and WNV;( 2) Generate fhmAb from protective Veloclmmune mAb to NiV and CHIKV;(3) Characterize Veloclmmune immune response and functionality of generated mAb;(4) Use recombinant genetics, mutagenesis, and somatic hypermutation to optimize mAb reactivity.

Public Health Relevance

Passive immunotherapy has an established track record in post exposure prophylaxis and treatment of infectious diseases and will continue to be a significant primary or complementary line of defense. With this project we will generate safe and specific fully human monoclonal antibody (fhmAb) therapeutics for Category A-C agents and establish a universal platform for efficiently generating these tools from entirely synthetic source materials, enabling a swift response to newly identified disease threats.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
New York
United States
Zip Code
Zhou, Yijun; Li, Xiao-Ping; Chen, Brian Y et al. (2017) Ricin uses arginine 235 as an anchor residue to bind to P-proteins of the ribosomal stalk. Sci Rep 7:42912
Aguilar, Jorge L; Varshney, Avanish K; Pechuan, Ximo et al. (2017) Monoclonal antibodies protect from Staphylococcal Enterotoxin K (SEK) induced toxic shock and sepsis by USA300 Staphylococcus aureus. Virulence 8:741-750
Chen, Han; Coseno, Molly; Ficarro, Scott B et al. (2017) A Small Covalent Allosteric Inhibitor of Human Cytomegalovirus DNA Polymerase Subunit Interactions. ACS Infect Dis 3:112-118
Pham, Alissa M; Santa Maria, Felicia Gilfoy; Lahiri, Tanaya et al. (2016) PKR Transduces MDA5-Dependent Signals for Type I IFN Induction. PLoS Pathog 12:e1005489
Basu, Debaleena; Kahn, Jennifer N; Li, Xiao-Ping et al. (2016) Conserved Arginines at the P-Protein Stalk Binding Site and the Active Site Are Critical for Ribosome Interactions of Shiga Toxins but Do Not Contribute to Differences in the Affinity of the A1 Subunits for the Ribosome. Infect Immun 84:3290-3301
Li, Melody M H; Bozzacco, Leonia; Hoffmann, Hans-Heinrich et al. (2016) Interferon regulatory factor 2 protects mice from lethal viral neuroinvasion. J Exp Med 213:2931-2947
Torres, AnnMarie; Luke, Joanna D; Kullas, Amy L et al. (2016) Asparagine deprivation mediated by Salmonella asparaginase causes suppression of activation-induced T cell metabolic reprogramming. J Leukoc Biol 99:387-98
Charles, Jermilia; Firth, Andrew E; LoroƱo-Pino, Maria A et al. (2016) Merida virus, a putative novel rhabdovirus discovered in Culex and Ochlerotatus spp. mosquitoes in the Yucatan Peninsula of Mexico. J Gen Virol 97:977-87
Taylor, Travis J; Diaz, Fernando; Colgrove, Robert C et al. (2016) Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology 496:186-193
Song, Jeongmin; Wilhelm, Cara L; Wangdi, Tamding et al. (2016) Absence of TLR11 in Mice Does Not Confer Susceptibility to Salmonella Typhi. Cell 164:827-8

Showing the most recent 10 out of 649 publications